Abstract
The pandemic of respiratory illness caused by a novel coronavirus (SARS-nCoV-2) is a global health crisis. Despite numerous preliminary results, there is as yet no treatment of proven efficacy for this condition. In this context, the pharmacological properties of lithium, better known as a treatment for mood disorders, merit closer examination. Lithium has shown in vitro efficacy at inhibiting the replication of coronaviruses responsible for gastrointestinal and respiratory diseases in animals. It has immunomodulatory properties that may be of additional benefit in moderating the host inflammatory response to the novel coronavirus (SARS-CoV-2). Furthermore, there is evidence that lithium may exert a protective action against upper respiratory infections and influenza-like illnesses in patients taking it for other indications. These promising reports must be balanced against the narrow therapeutic index and high risk of toxicity associated with lithium therapy, its documented interactions with several commonly used drugs, and the absence of evidence of its efficacy against coronaviruses responsible for human disease. Nevertheless, naturalistic studies of the risk of COVID-19 in patients already receiving lithium could provide in...Continue Reading
References
Feb 15, 1990·Biological Psychiatry·J D AmsterdamJ Rybakowski
Jun 1, 1987·Medical Hypotheses·R O Bach
Jan 1, 1980·Medical Microbiology and Immunology·G R SkinnerP Gallimore
Aug 1, 1997·International Journal of STD & AIDS·K A WardW W Dinsmore
Feb 26, 1998·Journal of Affective Disorders·J D AmsterdamJ Rybakowski
May 5, 2007·Avian Pathology : Journal of the W.V.P.A·Sally M HarrisonJulian A Hiscox
Aug 19, 2008·Virology·Ana AsenjoNieves Villanueva
Oct 20, 2009·Trends in Immunology·Eléonore BeurelRichard S Jope
May 17, 2011·PloS One·Xiaofeng RenGeorg Herrler
Apr 2, 2013·International Immunopharmacology·Abdulmecit AlbayrakSabri Selcuk Atamanalp
Jul 23, 2013·Neurochemistry International·Hong-Mei WangXiao-Jiang Sun
Sep 18, 2013·The Journal of Immunology : Official Journal of the American Association of Immunologists·Lijuan WangChengjiang Gao
Jan 29, 2014·Arthritis & Rheumatology·Takeshi MinashimaThorsten Kirsch
May 8, 2014·ACS Chemical Neuroscience·Ahmad Nassar, Abed N Azab
Mar 5, 2016·Clinical Pharmacokinetics·Patrick R Finley
Jun 28, 2016·Journal of Affective Disorders·Seline van den AmeeleManuel Morrens
May 31, 2017·European Journal of Drug Metabolism and Pharmacokinetics·Janthima Methaneethorn
Mar 17, 2018·Research in Veterinary Science·Hong-Jie LiJun Zhao
Mar 7, 2020·Cell·Markus HoffmannStefan Pöhlmann
Mar 19, 2020·Infectious Diseases of Poverty·Sasmita Poudel AdhikariHuan Zhou
Mar 25, 2020·Drug Development Research·Janusz K Rybakowski
Apr 24, 2020·Drug Discoveries & Therapeutics·Mohammed Noor EmbiHasidah Mohd Sidek
Apr 24, 2020·Immunity·Toshio Hirano, Masaaki Murakami
Apr 28, 2020·Drug Development Research·Soltan A Ebrahimi
May 2, 2020·Journal of Medical Toxicology : Official Journal of the American College of Medical Toxicology·Michael A CharyMichele M Burns
May 10, 2020·Science Immunology·Francesca Romana SpinelliMassimo Gadina
Jun 11, 2020·F1000Research·Jan K Nowak, Jarosław Walkowiak
Citations
Nov 27, 2020·Frontiers in Pharmacology·Janet SultanaGianluca Trifirò
Aug 17, 2021·Pharmacopsychiatry·Mohsen Khosravi
Oct 2, 2021·Proceedings of the National Academy of Sciences of the United States of America·Xiaolei LiuPeter S Klein
Oct 24, 2021·International Clinical Psychopharmacology·Naveen Manohar PaiGeetha Desai